Catalyst Pharma (CPRX) Closes $6M Direct Offering
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Join SI Premium – FREE
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has closed its previously announced offering of (i) 4.0 million shares of the Company's common stock, and (ii) warrants to purchase an aggregate of 1.2 million shares of the Company's common stock, in a registered direct public offering.
The aggregate offering price for each share and corresponding warrant was $1.50, resulting in gross proceeds of $6 million.
The common stock purchase warrants have a five-year term and an exercise price of $2.08 per share.
Roth Capital Partners acted as the exclusive placement agent for the transaction.
The aggregate offering price for each share and corresponding warrant was $1.50, resulting in gross proceeds of $6 million.
The common stock purchase warrants have a five-year term and an exercise price of $2.08 per share.
Roth Capital Partners acted as the exclusive placement agent for the transaction.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China SXT Pharmaceuticals (SXTC) files for 157.5M share offering by selling stockholders
- ARS Pharmaceuticals names Donn Casale as CEO, replacing co-founder
- James D. Burnham leaves RenX board, hired as director of growth & M&A
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
